Elena Jiménez-Martí

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 4

Top Topics

Breast Cancer Risk

High Throughput

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Marta Albanell, Sara S Oltra, Marta Orts-Arroyo, Maider Ibarrola-Villava, Fany Carrasco, Elena Jiménez-Martí, Andres Cervantes, Isabel Castro, Jose Martínez-Lillo, Gloria Ribas
RUNAT-BI: A Ruthenium(III) Complex as a Selective Anti-Tumor Drug Candidate against Highly Aggressive Cancer Cell Lines. Cancers 15 (1) (2022)
Elena Jiménez-Martí, Gema Hurtado-Genovés, María Aguilar-Ballester, Sergio Martinez-Hervas, Herminia González-Navarro
Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists. Nutrients 14 (18) (2022)
Marta Albanell, Sara S Oltra, Marta Orts-Arroyo, Maider Ibarrola-Villava, Fany Carrasco, Elena Jiménez-Martí, Andres Cervantes, Isabel Castro, Jose Martínez-Lillo, Gloria Ribas
RUNAT-BI: A Ruthenium(III) Complex as a Selective Anti-Tumor Drug Candidate against Highly Aggressive Cancer Cell Lines. Cancers 15 (1) (2022)
Marta Albanell, Sara S Oltra, Marta Orts-Arroyo, Maider Ibarrola-Villava, Fany Carrasco, Elena Jiménez-Martí, Andres Cervantes, Isabel Castro, Jose Martínez-Lillo, Gloria Ribas
RUNAT-BI: A Ruthenium(III) Complex as a Selective Anti-Tumor Drug Candidate against Highly Aggressive Cancer Cell Lines. Cancers 15 (1) (2022)